Diligence memo · auto-generated · as of July 2, 2026

Intellikine, Inc.

Intellikine, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Intellikine, Inc. operates in Biotechnology, based in LA JOLLA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Intellikine, Inc. has raised $16M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $16M on 2009-06-30.

Most recent recorded round closed around 2009-06-30.

Valuation (modeled)modeled

Provath models Intellikine, Inc. at approximately $636M (range $32M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.72× the median modeled value of Series B Biotechnology companies in 2007–2009 (21 peers) — value vs value, same stage and era. Within the normal band (72% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 17.0 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).

Modeled value ranks above 85% of those peers.

Closest niche peers: Ion Torrent Systems Inc, PhotoThera Inc, Taligen Therapeutics Inc, Atritech Inc, Barosense Inc.

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.